Melanoma

Showing NaN - NaN of 78

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified

Recruiting
  • Endometrial Cancer
  • +8 more
  • Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
  • Orlando, Florida
  • +21 more
Feb 2, 2023

Melanoma Trial in Philadelphia (Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • Mature dendritic cell (DC) vaccine
  • +2 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 2, 2023

Melanoma Trial in Worldwide (Nivolumab, Relatlimab)

Recruiting
  • Melanoma
  • Phoenix, Arizona
  • +84 more
Jan 31, 2023

Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)

Recruiting
  • Colorectal Carcinoma
  • +21 more
  • Dual X-ray Absorptiometry
  • +2 more
  • Birmingham, Alabama
  • +18 more
Jan 30, 2023

Metastatic Solid Tumors, NSCLC, Melanoma Trial in United States (INBRX-105 - PDL1x41BB antibody, Pembrolizumab)

Recruiting
  • Metastatic Solid Tumors
  • +7 more
  • Scottsdale, Arizona
  • +12 more
Jan 26, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +5 more
  • Los Angeles, California
  • +39 more
Jan 25, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, V937)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +5 more
  • Los Angeles, California
  • +28 more
Jan 25, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Quavonlimab, Vibostolimab)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +4 more
  • Los Angeles, California
  • +34 more
Jan 25, 2023

Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC) Trial in Philadelphia (Radiotherapy, MEDI4736, Tremelimumab)

Active, not recruiting
  • Metastatic
  • +4 more
  • Radiotherapy
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 6, 2023

Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))

Completed
  • Ovarian Cancer
  • +7 more
  • Enapotamab vedotin (HuMax-AXL-ADC)
  • Phoenix, Arizona
  • +40 more
Dec 12, 2022

Malignant Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) Trial in Worldwide (GEN1042, Pembrolizumab,

Recruiting
  • Malignant Solid Tumor
  • +5 more
  • GEN1042
  • +8 more
  • San Diego, California
  • +27 more
Dec 24, 2022

Breast Cancer, Breast Tumors, Colon Cancer Trial in United States (AZD6244, Dacarbazine, Erlotinib)

Active, not recruiting
  • Breast Cancer
  • +7 more
  • Detroit, Michigan
  • +3 more
Dec 22, 2022

Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)

Recruiting
  • Melanoma
  • Nivolumab
  • Nivolumab + Relatlimab Fixed Dose Combination
  • Birmingham, Alabama
  • +185 more
Dec 3, 2022

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)

Terminated
  • Melanoma
  • Talimogene Laherparepvec
  • +2 more
  • Birmingham, Alabama
  • +160 more
Nov 10, 2022

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

Improving Adolescent and Young Adult Self-Reported Data in

Recruiting
  • Breast Cancer, NOS
  • +11 more
  • Questionnaires
  • Fairbanks, Alaska
  • +313 more
Sep 20, 2022

Melanoma Trial in United States (TLPLDC, Placebo)

Completed
  • Melanoma
  • Birmingham, Alabama
  • +17 more
Sep 15, 2022

Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

Recruiting
  • Breast Cancer
  • +15 more
  • Goodyear, Arizona
  • +146 more
Aug 24, 2022

Advanced Cancer, Melanoma, NSCLC Trial in Worldwide (BMS-986205, Nivolumab, Ipilimumab)

Completed
  • Advanced Cancer
  • +2 more
  • Tucson, Arizona
  • +46 more
Aug 18, 2022

Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1429 more
Aug 17, 2022

Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T

Active, not recruiting
  • Urinary Bladder Cancer
  • +9 more
  • Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
  • Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
  • Miami, Florida
  • +10 more
Aug 9, 2022

Melanoma Trial in United States (CMP-001, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • Phoenix, Arizona
  • +12 more
Aug 1, 2022

Melanoma, Advanced Melanoma, Metastatic Melanoma Trial in United States (CMP-001, Nivolumab)

Active, not recruiting
  • Melanoma
  • +3 more
  • Phoenix, Arizona
  • +24 more
Aug 1, 2022

Melanoma, Advanced Melanoma, Metastatic Melanoma Trial in United States (CMP-001, Nivolumab)

Active, not recruiting
  • Melanoma
  • +3 more
  • Phoenix, Arizona
  • +19 more
Aug 1, 2022